Morphogen-IX is a Cambridge, UK–based biotech advancing a novel treatment for pulmonary arterial hypertension (PAH). The program directly targets a major pathway implicated in human genetic studies. The approach is based on 15 years of research led by Professor Nick Morrell and his team at the University of Cambridge’s Department of Medicine at Addenbrooke’s Hospital. Morphogen-IX worked with the British Heart Foundation Centre of Research Excellence at the University of Cambridge and with Cambridge Enterprise to license the underlying intellectual property. The company intends to use the newly raised funds to progress development of the PAH therapy. No operating metrics or revenues are disclosed in the article.

Total raised

$2M

Funding rounds

1

Latest round

Seed

Latest activity

Jan 2016